FDA Approves First Generic Dapagliflozin to Reduce HF Hospitalization Risk in Type 2 Diabetes

Today, the FDA approved the first generic versions of dapagliflozin (Farxiga; AstraZeneca) tablets to reduce the risk of heart failure (HF) in patients with type 2 diabetes.¹

The approval marks a significant step in improving affordability and access to a medication that has become a cornerstone in the management of both type 2 diabetes and cardiovascular risk.

Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is indicated to reduce the risk of hospitalization for HF in adults with type 2 diabetes mellitus who have either established cardiovascular disease or multiple cardiovascular risk factors. It is also approved as an adjunct to diet and exercise to improve glycemic control in this population.

SGLT2 inhibitors have emerged as a foundational therapy in type 2 diabetes due to their broad, multisystem benefits beyond glycemic control.² Recent evidence shows that, compared with dipeptidyl peptidase-4 inhibitors, SGLT2 inhibitors are associated with significantly lower risks of end-stage kidney disease (adjusted hazard ratio [aHR], 0.34), acute kidney injury (aHR, 0.66), major adverse cardiovascular events (aHR, 0.67), all-cause mortality (aHR, 0.58), and hepatic decompensation (aHR, 0.65) in high-risk patients with type 2 diabetes and cirrhosis.

These findings reinforce the growing role of SGLT2 inhibitors as cardiorenal-metabolic therapies that may simultaneously protect the heart, kidneys, and liver. However, their observational nature underscores the need for prospective studies to confirm causality.

The approval of generic dapagliflozin comes at a critical time, as type 2 diabetes continues to pose a substantial public health burden in the US. More than 40 million individuals nationwide are living with diabetes, with approximately 90% to 95% of cases classified as type 2 diabetes, according to the CDC.¹ The chronic condition develops over years and is characterized by insulin resistance and impaired glucose regulation, often leading to complications such as cardiovascular disease, kidney disease, and HF.

The FDA’s decision to introduce generic competition is expected to lower costs and broaden patient access to dapagliflozin, particularly for those at high risk of cardiovascular events. Improved affordability may also support adherence to guideline-recommended therapies, which is a persistent challenge in chronic disease management.

The prescribing information for generic dapagliflozin includes the same contraindications, warnings, and precautions as the branded product. The medication is contraindicated in patients with a history of serious hypersensitivity reactions to dapagliflozin or any of its components. Notably, warnings include the risk of diabetic ketoacidosis, particularly in patients with type 1 diabetes (for whom the drug is not indicated), as well as other forms of ketoacidosis and volume depletion.

Common adverse events observed in clinical trials include female genital mycotic infections, nasopharyngitis, and urinary tract infections. As with all SGLT2 inhibitors, clinicians should monitor patients for signs of dehydration, changes in renal function, and other potential complications.

The approval of generic dapagliflozin reflects ongoing efforts to enhance competition in the pharmaceutical market while maintaining rigorous standards for safety and efficacy. As cardiovascular and metabolic diseases continue to intersect, expanded access to therapies like dapagliflozin may play a key role in improving outcomes for patients with type 2 diabetes.

The FDA approved dapagliflozin tablets from multiple generic drug applicants. Because of this, the agency encouraged health care providers to consult the Approved Drug Products with Therapeutic Equivalence Evaluations, also known as the Orange Book, for more details.

References

1. FDA approves first generic dapagliflozin tablets. FDA. April 7, 2026. Accessed April 7, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-approves-first-generic-dapagliflozin-tablets

2. Steinzor P. SGLT2s linked to lower cardiorenal, hepatic risks in type 2 diabetes. AJMC^®. February 23, 2026. Accessed April 7, 2026. https://www.ajmc.com/view/sglt2is-linked-to-lower-cardiorenal-hepatic-risks-in-type-2-diabetes